Drug intelligence / Profile preview

Folic Prevent

Development stage: Unknown
Lead developer: Laboratorios Laproff
Modality: Small Molecules
Administration: Oral

Overview

Folic Prevent is a branded folic acid (vitamin B9) supplement developed and marketed by Laboratorios Laproff. Formulated as 400 µg oral tablets, it serves as an essential cofactor in the synthesis of nucleoproteins and the maintenance of normal erythropoiesis. The primary clinical indication for Folic Prevent is periconceptional supplementation to prevent neural tube defects (NTDs) such as spina bifida and anencephaly in the developing fetus. It is also indicated for the prevention and treatment of folate deficiency during pregnancy, lactation, and other periods of increased physiological demand. The product is an approved pharmaceutical in several Latin American markets, including Colombia and Venezuela.

Brand names: Folic Prevent
Other names: folic acid

Targets

FOLR1 (FRα)DNA

Beyond the preview

Go deeper on Folic Prevent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Folic Prevent.

Explore the full profile